Psychemedics Co. (NASDAQ:PMD) Major Shareholder Powell Anderson Capital Partne Purchases 75,000 Shares

Psychemedics Co. (NASDAQ:PMD) major shareholder Powell Anderson Capital Partne bought 75,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $2.67 per share, for a total transaction of $200,250.00. Following the completion of the purchase, the insider now owns 494,556 shares in the company, valued at $1,320,464.52. This trade represents a 17.88 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Powell Anderson Capital Partne also recently made the following trade(s):

• On Tuesday, December 10th, Powell Anderson Capital Partne purchased 7,473 shares of Psychemedics stock. The stock was acquired at an average price of $2.59 per share, with a total value of $19,355.07.

Psychemedics Stock Down 1.8 %

Shares of NASDAQ PMD traded down $0.05 during mid-day trading on Thursday, hitting $2.67. The company had a trading volume of 112,324 shares, compared to its average volume of 21,191. Psychemedics Co. has a 1-year low of $1.63 and a 1-year high of $3.93. The company has a market capitalization of $15.74 million, a PE ratio of -5.24 and a beta of 0.65. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.59 and a quick ratio of 1.59. The business’s 50-day simple moving average is $2.37 and its 200 day simple moving average is $2.32.

About Psychemedics

Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol.